Organogenesis Holdings First Quarter 2025 Earnings: Misses Expectations

Organogenesis Holdings (NASDAQ:ORGO) First Quarter 2025 Results

Key Financial Results

• Revenue: US$86.7m (down 21% from 1Q 2024).
• Net loss: US$21.6m (loss widened by US$19.5m from 1Q 2024).
• US$0.17 loss per share (further deteriorated from US$0.016 loss in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Organogenesis Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.5%. Earnings per share (EPS) also missed analyst estimates.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 39% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Organogenesis Holdings has 2 warning signs (and 1 which can't be ignored) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.